nach oben

CardioVascular and Interventional Radiology

Erschienen in:

01.02.2015 | Review

Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

verfasst von: Gianluigi Orgera, Miltiadis Krokidis, Matteo Cappucci, Sofia Gourtsoyianni, Marcello Andrea Tipaldi, Adam Hatzidakis, Alberto Rebonato, Michele Rossi

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Within the group of Gastro-Entero-Pancreatic Neuroendocrine tumours (GEP-NETs), several heterogeneous malignancies are included with a variety of clinical manifestations and imaging characteristics. Often these cases are inoperable and minimal invasive treatment offered by image-guided procedures appears to be the only option. Interventional radiology offers a valid solution in the management of primary and metastatic GEP-NETs. The purpose of this review article is to describe the current status of the role of Interventional Radiology in the management of GEP-NETs.

Amodio A, Crosetti S (2010) Tumori Neuroendocrini. In: Lopez M, Gebbia N, Cascinu S, Marchetti P (eds) Oncologia Medica Pratica. Società Editrice Universo, Roma, pp 2173–2194

Muniraj T, Vignesh S, Shetty S et al (2013) Pancreatic neuroendocrine tumor. Dis Mon 59:5–19PubMedCrossRef

Colao A, Faggiano A, Milone F (2011) Tumori Neuroendocrini. In: Lenzi A, Lom-bardi G, Martino E, Vigneri R (eds) Endocrinologia Clinica. Edizioni Minerva Medica, Torino, pp 217–224

Klöppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrine Related Cancer 18:S1–S16PubMedCrossRef

Bosman FT, Carneiro F, Hruban R et al (2010) WHO classification of tumours of the digestive system. IARC Press, Lyon

Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712PubMedCrossRef

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef

Burns WR, Edil BH (2011) Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol 13:24–34CrossRef

Orgera G, Krokidis M, Monfardini L et al (2011) High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases. Cardiovasc Intervent Radiol 34:419–423PubMedCrossRef

10.

Drymousis P, Raptis DA, Spalding D et al (2014) Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis. HPB (Oxford) 16(5):397–406CrossRef

11.

Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M (2012) Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg. 16(10):1981–1992PubMedCrossRef

12.

Oberg K, Knigge U, Kwekkeboom D, ESMO Guidelines Working Group et al (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7):vii124–vii130PubMed

13.

Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176PubMedCrossRef

14.

Ramage JK, Ahmed A, Ardill J, UK and Ireland Neuroendocrine Tumour Society et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NET’s). Gut 61(1):6–32PubMedCentralPubMedCrossRef

15.

Gouya H, Vignaux O, Augui J et al (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181(4):987–992PubMedCrossRef

16.

Arnold R, Chen YJ, Costa F, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society et al (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 90(2):227–233PubMedCrossRef

17.

Campana D, Nori F, Piscitelli L et al (2007) Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25(15):1967–1973PubMedCrossRef

18.

Arnold R, Wilke A, Rinke A et al (2008) Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 6(7):820–827PubMedCrossRef

19.

Kulke MH, Benson AB III, Bergsland E et al (2012) Neuroendocrine tumors. J Natl Compr Cancer Netw 10:724–764

20.

Peppa M, Brountzos E, Economopoulos N et al (2009) Embolization as an alternative treatment of insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome. Cardiovasc Intervent Radiol 32:807–811PubMedCrossRef

21.

Moore T, Peterson L, Harington D (1982) Successful arterial embolization of an insulinoma. JAMA 248:1953–1955CrossRef

22.

Uflacker R (1992) Arterial embolization as definitive treatment for benign insulinoma of the pancreas. J Vasc Interv Radiol 3:441–639 discussion 644–666CrossRef

23.

Rott G, Biggemann M, Pfohl M (2008) Embolization of an insulinoma of the pancreas with trisacryl gelatin microspheres as definitive treatment. Cardiovasc Intervent Radiol 31:659–662PubMedCrossRef

24.

Ben-Ishay O, Linder R, Ofer A et al (2012) Hypervascular lesion in the head of the pancreas. Preoperative angiography and selective embolization results in bloodless operation. JOP 13:671–673PubMed

25.

Rossi M, Orgera G, Hatzidakis A et al (2014) Minimally invasive ablation treatment for locally advanced pancreatic adenocarcinoma. Cardiovasc Intervent Radiol 37:203–210PubMedCrossRef

26.

Goldberg SN, Mallery S, Gazelle GS et al (1999) EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc 50:392–401PubMedCrossRef

27.

Date RS, Biggins J, Paterson I et al (2005) Development and validation of an experimental model for the assessment of radiofrequency ablation of pancreatic parenchyma. Pancreas 30:266–271PubMedCrossRef

28.

Matsui Y, Nakagawa A, Kamiyama Y et al (2000) Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas 20:14–20PubMedCrossRef

29.

Limmer S, Huppertb P, Juettea V et al (2009) Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol 21:1097–1101PubMedCrossRef

30.

Akhlaghpoor S, Dahi F, Alinaghizadeh M et al (2011) CT fluoroscopy-guided transcaval radiofrequency ablation of insulinoma. J Vasc Interv Radiol 22:409–410PubMedCrossRef

31.

Wu P, Pan C, Huang Z et al (2010) Percutaneous radiofrequency ablation approach through the spleen: initial case report for pancreatic tail gastrinoma. Chin J Cancer 29:836–841PubMedCrossRef

32.

Hlavsa J, Procházka V, Kala Z et al (2011) Radiofrequency ablation of pancreatic neuroendocrine tumor. Klin Onkol 24:209–215PubMed

33.

Fegrachi S, Besselink MG, van Santvoort HC et al (2014) Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford) 16:119–123CrossRef

34.

Chen Q, Zhu X, Chen Q et al (2013) Unresectable giant pancreatic neuro-endocrine tumor effectively treated by HIFU: a case report and a review of the literature. Pancreatology 13:634–638PubMedCrossRef

35.

Dunki-Jacobs EM, Philips P, Martin RC 2nd (2014) Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 218(2):179–187PubMedCrossRef

36.

Scheffer HJ, Nielsen K, de Jong MC et al (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25(7):997–1011PubMedCrossRef

37.

Mayo SC, De Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17:3129–3136PubMedCrossRef

38.

John BJ, Davidson BR (2012) Treatment options for unresectable neuroendocrine liver metastases. Expert Rev Gastroenterol Hepatol 6:357–369PubMedCrossRef

39.

Frilling A, Sotiropoulos GC, Li J et al (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12:361–379CrossRef

40.

McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81:1007–1009PubMedCrossRef

41.

Zeitels J, Naunheim K, Kaplan EL et al (1982) Carcinoid tumors: a 37-year experience. Arch Surg 117:732–737PubMedCrossRef

42.

Panzuto F, Merola E, Rinzivillo M et al (2014) Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 43:212–218PubMedCrossRef

43.

Dromain C, de Baere T, Baudin E et al (2003) MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 180(1):121–128PubMedCrossRef

44.

Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602PubMedCrossRef

45.

Strosberg JR, Choi J, Cantor AB et al (2006) Selective hepatic artery embolization for treatment of patients with meta-static carcinoid and pancreatic endocrine tumors. Cancer Control 13:72–78PubMed

46.

Sofocleous CT, Petre EN, Gonen M et al (2013) Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 25:22–30CrossRef

47.

Kress O, Wagner HJ, Wied M et al (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68:94–101PubMedCrossRef

48.

Korse CM, Bonfrer JM, Prevoo W et al (2011) Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumour Biol 32(4):647–652PubMedCrossRef

49.

Liao XF, Yi JL, Li XR et al (2004) Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10(13):1885–1889PubMed

50.

Strosberg JR, Weber JM, Choi J et al (2012) A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 23(9):2335–2341PubMedCrossRef

51.

Ruutiainen AT, Soulen MC, Tuite CM et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18:847–855PubMedCrossRef

52.

Pitt SC, Knuth J, Keily JM et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12:1951–1960PubMedCentralPubMedCrossRef

53.

Maire F, Lombard-Bohas C, O’Toole D et al (2012) Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases of well-differentiated midgut endocrine tumors. A prospective randomized study. Neuroendocrinology 96:294–300PubMedCrossRef

54.

Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47(1):177–182PubMedCrossRef

55.

De Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855–861PubMedCrossRef

56.

Gaur SK, Friese JL, Sadow CA et al (2011) Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 34:566–572PubMedCrossRef

57.

Bhagat N, Reyes DK, Lin M et al (2013) Phase II study of chemoembolization with drug-elutingbeads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 36:449–459PubMedCentralPubMedCrossRef

58.

Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56(3):609–617PubMedCrossRef

59.

Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin ⁹⁰Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279PubMedCrossRef

60.

King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929PubMedCrossRef

61.

Cao CQ, Yan TD, Bester L et al (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97:537–543PubMedCrossRef

62.

Saxena A, Chua TC, Bester L et al (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251:910–916PubMedCrossRef

63.

Kalinowski M, Dressler M, Konig A et al (2009) Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79:137–142PubMedCrossRef

64.

Paprottka PM, Hoffmann RT, Haug A et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35:334–342PubMedCrossRef

65.

Rhee TK, Lewandowski RJ, Liu DM et al (2008) ⁹⁰Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247:1029–1035PubMedCrossRef

66.

Jansen MC, Van Hillegersberg R, Schoots IG et al (2010) Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147:686–695PubMedCrossRef

67.

Vyleta M, Coldwell D (2011) Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011:785315PubMedCentralPubMedCrossRef

68.

Limouris GS, Chatziioannou A, Kontogeorgakos D et al (2008) Selective hepatic arterial infusion of In-111-DTPA-Phe1octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35(10):1827–1837PubMedCrossRef

69.

Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021PubMedCrossRef

70.

Akyildiz HY, Mitchell J, Milas M et al (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 148:1288–1293PubMedCrossRef

71.

Mazzaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19PubMedCrossRef

72.

Martin RC, Scoggins CR, McMasters KM (2010) Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 17:171–178PubMedCrossRef

73.

Groeschl RT, Pilgrim CH, Hanna EM et al (2013) Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 259(2):1195–1200

74.

Shapiro RS, Shafir M, Sung M et al (1998) Cryotherapy of metastatic carcinoid tumors. Abdom Imaging 23:314–317PubMedCrossRef

75.

Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14:175–183PubMedCrossRef

76.

Bilchik AJ, Sarantou T, Foshag LJ et al (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122:1040–1047 discussion 1047–1048PubMedCrossRef

77.

Seifert JK, Morris DL (1999) World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1923:109–113 discussion 113–114CrossRef

Titel: Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)
verfasst von: Gianluigi Orgera
Miltiadis Krokidis
Matteo Cappucci
Sofia Gourtsoyianni
Marcello Andrea Tipaldi
Adam Hatzidakis
Alberto Rebonato
Michele Rossi
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 1/2015
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-014-1005-z

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Abstract

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Endovascular Aneurysm Repair: Is Imaging Surveillance Robust, and Does It Influence Long-term Mortality?

Local Control of Perivascular Malignant Liver Lesions Using Percutaneous Irreversible Electroporation: Initial Experiences

A Newly Designed Stent for Management of Malignant Distal Duodenal Stenosis

Management of Gastric Varices in the Pediatric Population with Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Utilizing Sodium Tetradecyl Sulfate Foam Sclerosis with or without Partial Splenic Artery Embolization

Prospective Evaluation of the Optimal Duration of Bed Rest After Vascular Interventions Using a 3-French Introducer Sheath

Is Prostatic Artery Embolization Similar to Uterine Artery Embolization?

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie